Immunomedics, Inc. (NASDAQ: IMMU) is committed to being a leading, innovative biopharmaceutical company dedicated to improving a patient’s health and quality of life with novel antibody–based therapeutics for the treatment of cancer, autoimmune and other serious diseases. The company’s work is driven by scientific excellence and the highest standards in a culture of integrity, pride and dedication. In doing so, Immunomedics creates value for its shareholders and a rewarding environment for its employees. For more information, visit the company’s website at www.immunomedics.com.